Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd are preparing to enter the fast-growing market for Semaglutide — a ...

When a man suddenly collapsed during a televised White house event about weight-loss drugs, it sparked widespread speculation ...

U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-l ...

As we found in our recent research, our brains also have powerful mechanisms for defending body weight – and can sort of ...